[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transthyretin-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transthyretin-amyloidosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,99,124,149,174,198,221,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420",false,"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","ALL","18 Years","75 Years",{"count":20,"type":21},587,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[27,28,29,30,31,32],"Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[27,34,35,36,37,38],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","RECRUITING","2026-06-25",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2025-05-12",{"date":47,"type":21},"2032-12",{"name":49,"class":50},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",103,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100551878","non-interventional-study-of-patients-with-transthyretin-attr-amyloidosis-100551878","NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis","MaesTTRo","Inclusion Criteria:\n\n* Patient willing and able to provide written informed consent to participate in the study\n* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis\n* Aged ≥18 years at the time of signing the informed consent\n* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional trial for ATTR amyloidosis\n* Involvement in the planning and\u002For conduct of the current study\n* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)\n* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers","130 Years",{"count":62,"type":21},1850,"OBSERVATIONAL","The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.",[29,34,66,67,68,69],"ATTRv-PN","ATTR","ATTR-Mixed","hATTR",[27,36,71,72,73,74,75,76,77,78,79,67,80,81,32,82,83,84,85,86,87,88],"Hereditary transthyretin-mediated (hATTR) amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","Transthyretin amyloidosis","TTR-mediated amyloidosis","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","Eplontersen","Non-interventional","Observational","Real-world","2026-06-19",{"date":91,"type":43},"2026-06-23",{"date":93,"type":43},"2024-06-25",{"date":95,"type":21},"2031-12-29",{"name":97,"class":50},"AstraZeneca",74,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100608754","the-eplontersen-pregnancy-and-lactation-outcomes-study-100608754","NCT07205666","The Eplontersen Pregnancy and Lactation Outcomes Study","The Eplontersen Pregnancy and Lactation Outcomes Study (EPPRO): A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen","EPPRO","Inclusion Criteria:\n\n* all pregnancy and\u002For lactation cases with exposure to eplontersen and a diagnosis of an approved indication for treatment with eplontersen\n* all adverse event reports in infants in the first 12 months of age that are or can be linked to pregnancy or lactation reports in individuals previously diagnosed with an approved indication and exposed to eplontersen during pregnancy or lactaction\n\nExclusion Criteria:\n\n* all case reports considered invalid (i.e. minimum data is not provided at first report nor follow-up), or where reporter indicates that they do not wish to be contacted to obtain follow-up information, or the reporter\u002Fpatient cannot be identified",{"count":108,"type":21},10,"The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and\u002For lactation.",[29],[85,112,113,114],"pregnancy","Wainua","Wainzua","2026-06-18",{"date":117,"type":43},"2026-06-22",{"date":119,"type":43},"2025-11-30",{"date":121,"type":21},"2035-12-30",{"name":97,"class":50},1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100642140","long-term-safety-of-eplontersen-treated-attr-patients-and-in-liver-transplant-and-severely-hepatic-impaired-subpopulations-100642140","NCT07654855","Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations","Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)","sTTRing","Inclusion Criteria:\n\n1. D8450R00003 participants who consented to have their data used for future related research studies.\n2. D8450R00003 participants who initiated eplontersen treatment up to 1-year prior to enrolment into D8450R00003 study observation period, irrespective of ATTR phenotype or genotype. For the comparative analyses, patients unexposed to eplontersen treatment and who initiated another ATTR treatment during D8450R00003 study observation period will be included\n\nExclusion Criteria:\n\n1. Patients with exposure to eplontersen more than 1-year prior to enrolment into D8450R00003 study.\n2. Patients who participated in an interventional ATTR study in the 12-months prior to enrolment into D8450R00003 study.",{"count":133,"type":21},320,"The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic impairment, as well as to assess long-term safety among all new users of eplontersen; all are areas of missing information\n\nPrimary objectives are:\n\n1. To describe demographic and clinical characteristics of patients at eplontersen initiation, including the prevalence of prior liver transplant (overall and by reason for liver transplant), and the prevalence of severe hepatic impairment; and to describe patients in these subgroups (prior liver transplant, severe hepatic impairment).\n2. To describe long-term safety in patients who initiate eplontersen treatment, including onset of new clinical events, abnormal laboratory values and serious adverse events.",[29,136,137],"Transthyretin Amyloidosis With Cardiomyopathy","Transthyretin Amyloidosis With Polyneuropathy",[139],"ATTR, Transthyretin amyloidosis","NOT_YET_RECRUITING","2026-06-11",{"date":143,"type":43},"2026-06-17",{"date":145,"type":21},"2026-09-01",{"date":147,"type":21},"2032-01-29",{"name":97,"class":50},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":123},"100643249","concordance-for-transthyretin-amyloidosis-between-synovial-biopsy-and-anterior-carpal-ligament-biopsy-100643249","NCT07644325","Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy","Assessment of Diagnostic Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy in Patients Who Underwent Endoscopic Carpal Tunnel Syndrome Surgery","ATTR2026","Inclusion Criteria:\n\n* Adult patient with Health Insurance\n* Clinical diagnosis + carpal tunnel EMG\n* Validated indication for carpal tunnel surgery\n* Signed informed consent\n* Patient at risk for postoperative complications (bilateral carpal tunnel syndrome, heart failure, atrial fibrillation, elderly patients)\n\nExclusion Criteria:\n\n* Need for open carpal tunnel surgery.\n* Pregnant women\n* Adults under guardianship",{"count":158,"type":21},500,[160],"NA","Transthyretin amyloidosis (ATTR) is an underdiagnosed condition that can present early as carpal tunnel syndrome, sometimes preceding cardiac involvement by several years. The recent emergence of new treatments underscores the importance of early diagnosis. Synovial biopsy performed during open carpal tunnel surgery is considered the gold standard for local screening, but it is less accessible, more difficult, and riskier to perform via endoscopy-a minimally invasive surgical technique that is currently the standard at our center and is becoming increasingly widespread.\n\nThe anterior annular ligament of the carpus constitutes an alternative tissue to the synovium, easily accessible via endoscopy, safe, and standardizable.\n\nIn this study, the systematic performance of an annular ligament biopsy in conjunction with a synovial biopsy during endoscopic carpal tunnel surgery would allow for the evaluation of the diagnostic concordance of the ligament biopsy by comparing it to the results obtained using the gold standard method. This strategy would also provide an opportunity to analyze the feasibility of systematic screening for ATTR on the ligament during endoscopic procedures.\n\nThis approach could offer a practical and innovative method for the early identification of at-risk patients and facilitate appropriate and timely management of the condition.",[163,29],"Carpal Tunnel","2026-06-08",{"date":166,"type":43},"2026-06-12",{"date":168,"type":43},"2026-05-27",{"date":170,"type":21},"2027-05-27",{"name":172,"class":173},"Clinique Saint Jean, France","OTHER",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100586901","retrospective-identification-of-scintigraphic-cardiac-amyloidosis-risca-100586901","NCT06921408","Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)","Retrospective Identification of Scintigraphic Cardiac Amyloidosis Using Deep Learning-based Model","RISCA","Inclusion Criteria:\n\n* Adults (≥ 18 years)\n* Patients who underwent bone scintigraphy with 99mTc-HMDP\u002FDPD\u002FPYP for any indication\n* Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist\n\nExclusion Criteria:\n\n* Patients under legal protection\n* Patients refusing the reuse of their data after individual information",{"count":183,"type":21},57,"This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.",[186,29],"Cardiac Amyloidosis",[186,188,189],"Bone Scintigraphy","Deep learning","2026-05-14",{"date":192,"type":43},"2026-05-15",{"date":145,"type":21},{"date":195,"type":21},"2027-12-01",{"name":197,"class":173},"University Hospital, Lille",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":123},"100497534","phase-2-characterizing-iodine-124-evuzumitide-at-01-in-systemic-amyloidosis-100497534","NCT05758493","Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis","Inclusion Criteria:\n\n1. Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance\n2. Patient willing to consent for the study and undergo the study procedures.\n\nExclusion Criteria:\n\n1. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol\n2. Has a known allergy to potassium iodide treatment or to gadolinium.\n3. Patients on dialysis or those with eGFR \\\u003C30 cc\u002Fmin\u002F1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI.\n4. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration","40 Years","90 Years",{"count":207,"type":21},150,[209],"PHASE2","This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET\u002FMRI). In a subgroup of patients who are unable to undergo PET\u002FMR, computed tomography will be used instead of MRI (i.e. PET\u002FCT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.",[27,29],"2026-04-06",{"date":214,"type":43},"2026-04-13",{"date":216,"type":43},"2023-01-10",{"date":218,"type":21},"2028-03-10",{"name":220,"class":173},"Oregon Health and Science University",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":123},"100538512","phenotyping-and-characterization-of-wtattr-cm-trace-1-100538512","NCT06291805","Phenotyping and Characterization of wtATTR-CM (TRACE 1)","Phenotyping and Characterization of Danish Wild-type Transthyretin Amyloidosis Cardiomyopathy Patients: A Cross-sectional Study","Group 1: wtATTR-CM patients\n\nInclusion Criteria:\n\n* Patients \\> 18 years diagnosed with ATTRwt-CM by:\n* endomyocardial biopsy\n* DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing.\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* AL amyloidosis (light-chain amyloidosis).\n* Myelomatosis\n* Waldenström macroglobulinemia\n\nGroup 2: Control group\n\nInclusion Criteria:\n\n* Patients \\> 18 years\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* Known cardiovascular disease including ischemic heart disease, heart failure, atrial fibrillation, presence of a pacemaker, or malignant hypertension. Well-controlled hypertension is acceptable.\n* Suspicion of cardiac amyloidosis assessed through clinical history, physical examination, ECG, and echocardiography focusing on \"red flags\":\n* Echocardiography with:\n* Myocardial hypertrophy (septum \\>11 mm)\n* Apical sparing in LV-GLS\n* Infiltrative changes in the right ventricle free wall, thickened atrioventricular valves, or thickened atrial septum\n* Symptoms of polyneuropathy\n* Low voltage on ECG or discrepancy between left ventricular thickness and ECG amplitude indicative of low voltage\n* Atrioventricular block (AV block)\n* Bilateral carpal tunnel syndrome\n* Surgery for spinal stenosis\n* Elevated troponin I or NT-pro-BNP",true,{"count":230,"type":21},120,"Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.",[29,233,234,235],"Transthyretin Amyloid Cardiomyopathy","Wild-Type Transthyretin-Related (ATTR)Amyloidosis","Quality of Life","2025-08-12",{"date":238,"type":43},"2025-08-15",{"date":240,"type":43},"2024-02-20",{"date":242,"type":21},"2025-12",{"name":244,"class":173},"Steen Hvitfeldt Poulsen",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":253,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":123},"100483652","prevalence-and-prediction-of-attr-in-ambulatory-patients-with-hfpef-100483652","NCT05577819","Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF","Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction","TTRinHFpEF","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of HFpEF.\n* Age ≥65 years old\n\nExclusion Criteria:\n\n* End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \\\u003C15mL\u002Fmin)\n* no history of HFrEF (LVEF\\\u003C40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS\u002FMI, etc\n* Negative 99mTc-pyrophosphate scan within a year\n* Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan\n* Known diagnosis of amyloidosis\n* Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)","65 Years",{"count":255,"type":21},515,[160],"Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.",[29,259,260,27],"Heart Failure","Heart Failure, Diastolic",[29,259,260,27],"2024-12-06",{"date":264,"type":43},"2024-12-09",{"date":266,"type":43},"2020-10-02",{"date":268,"type":21},"2026-12-31",{"name":270,"class":173},"Massachusetts General Hospital"]